Lymphopenia during chemoradiation-foe or friend.
chemoradiation
head-and-neck cancer
lymphopenia
Journal
Ecancermedicalscience
ISSN: 1754-6605
Titre abrégé: Ecancermedicalscience
Pays: England
ID NLM: 101392236
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
05
2020
entrez:
4
11
2020
pubmed:
5
11
2020
medline:
5
11
2020
Statut:
epublish
Résumé
Severe lymphopenia during treatment is considered to be a poor prognostic factor. The current literature lacks information regarding its impact on various outcomes in locally advanced head-and-neck cancer patients in a prospective setting. We recently published a randomised study comparing cisplatin-radiation with nimotuzumab cisplatin-radiation. The database of this study was used for the present analysis. The impact of severe lymphopenia (grade 4 lymphopenia) on progression-free survival (PFS), locoregional control (LRC) and overall survival (OS) was studied using the Kaplan-Meier method and Cox regression analysis. The binary logistic regression analysis was used to see the effect of various factors on the development of severe lymphopenia. We had a total of 536 patients, of which 521 patients (97.7%) developed lymphopenia. Grade 1 lymphopenia was noted in 10 (1.9%) patients, grade 2 in 100 (18.8%), grade 3 in 338 (63.1%) and grade 4 in 73 (13.7%) patients. The median PFS was 20.53 and 60.33 months in severe and non-severe lymphopenia, respectively (hazard ratio, 0.797; The occurrence of severe lymphopenia was not significantly associated with the outcomes. Gender is the only risk factor significantly linked to severe lymphopenia.
Sections du résumé
BACKGROUND
BACKGROUND
Severe lymphopenia during treatment is considered to be a poor prognostic factor. The current literature lacks information regarding its impact on various outcomes in locally advanced head-and-neck cancer patients in a prospective setting.
METHODS
METHODS
We recently published a randomised study comparing cisplatin-radiation with nimotuzumab cisplatin-radiation. The database of this study was used for the present analysis. The impact of severe lymphopenia (grade 4 lymphopenia) on progression-free survival (PFS), locoregional control (LRC) and overall survival (OS) was studied using the Kaplan-Meier method and Cox regression analysis. The binary logistic regression analysis was used to see the effect of various factors on the development of severe lymphopenia.
RESULTS
RESULTS
We had a total of 536 patients, of which 521 patients (97.7%) developed lymphopenia. Grade 1 lymphopenia was noted in 10 (1.9%) patients, grade 2 in 100 (18.8%), grade 3 in 338 (63.1%) and grade 4 in 73 (13.7%) patients. The median PFS was 20.53 and 60.33 months in severe and non-severe lymphopenia, respectively (hazard ratio, 0.797;
CONCLUSION
CONCLUSIONS
The occurrence of severe lymphopenia was not significantly associated with the outcomes. Gender is the only risk factor significantly linked to severe lymphopenia.
Identifiants
pubmed: 33144877
doi: 10.3332/ecancer.2020.1109
pii: can-14-1109
pmc: PMC7581337
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1109Informations de copyright
© the authors; licensee ecancermedicalscience.
Déclaration de conflit d'intérêts
None declared.
Références
Cancer Chemother Pharmacol. 2011 Nov;68(5):1305-13
pubmed: 21448592
Clin Breast Cancer. 2012 Aug;12(4):264-9
pubmed: 22591634
J Thorac Oncol. 2011 Apr;6(4):824-33
pubmed: 21173711
Cancer Sci. 2018 Mar;109(3):785-793
pubmed: 29285832
Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):812-823
pubmed: 31344435
Eur J Cancer. 2013 May;49(7):1673-82
pubmed: 23265706
J Pediatr Hematol Oncol. 2007 Jan;29(1):48-52
pubmed: 17230066
Daru. 2017 Apr 24;25(1):12
pubmed: 28438219
Arch Otolaryngol Head Neck Surg. 1987 Nov;113(11):1200-6
pubmed: 3499156
Ann Oncol. 2009 Jun;20(6):1105-12
pubmed: 19174452
J Urol. 2013 Feb;189(2):454-61
pubmed: 23041457
Br J Cancer. 1974 Sep;30(3):215-21
pubmed: 4451626
Head Neck. 2014 Dec;36(12):1747-53
pubmed: 24174270
Cancer. 2019 Sep 15;125(18):3184-3197
pubmed: 31150120
Oncologist. 2019 Aug;24(8):e677-e686
pubmed: 31040254
J Natl Compr Canc Netw. 2015 Oct;13(10):1225-31
pubmed: 26483062
J Clin Oncol. 2018 Apr 10;36(11):1064-1072
pubmed: 29220295
Oncoimmunology. 2012 Jul 1;1(4):432-440
pubmed: 22754761
Otolaryngol Head Neck Surg. 1986 Sep;95(2):142-52
pubmed: 2954014
Gynecol Oncol. 2016 Jan;140(1):76-82
pubmed: 26571200